# Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

> **NCT04026113** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 438 (actual)

## Conditions studied

- Functional Constipation
- Irritable Bowel Syndrome With Constipation

## Interventions

- **DRUG:** Linaclotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04026113
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-01
- **Primary completion:** 2024-05-20
- **Final completion:** 2024-05-29
- **Target enrollment:** 438 (ACTUAL)
- **Last updated:** 2024-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04026113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04026113, "Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04026113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*